Madrigal Pharma (MDGL) Announces Delay in Release of Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/26/2026

1. ON
2. SYNA
3. SPY
4. MU
5. DRI
6. NKE
7. NVDA
8. FDXF
9. SPCX
10. INCY

Go back to Madrigal Pharma (MDGL) Announces Delay in Release of Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

December 30, 2021 8:00 AM EST

CONSHOHOCKEN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease, presumed NASH.

Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, Although the blinded study data were delivered to the vendor conducting the statistical analyses on time, unexpected staffing issues at the vendor delayed their analyses of the initial MRI-PDFF and lipid data planned for release by year end. We now expect to announce topline 52-week... More